论文部分内容阅读
目的:探讨亚甲蓝病毒灭活血浆制备方法及对凝血因子的影响。为临床使用病毒灭活血浆治疗提供剂量及安全使用依据。为病毒灭活血浆推广提供理论基础。方法:选取100份全血分离制备的血浆进行病毒灭活前后留样,制成新鲜冰冻血浆后融化,采用亚甲蓝光化学法检测灭活前后各成分及凝血因子活性的变化。结果:灭活前纤维蛋白原为(2.24±0.12)mg/m L、凝血VIII因子为(0.78±0.09)IU/m L、凝血酶原时间为(14.02±2.63)S,活化的部分凝血活酶时间APTT为(34.62±4.76)S。残留白细胞计数(3.0±2.1)×10~6/L灭活后纤维蛋白原为(2.10±0.14)mg/m L、凝血VIII因子为(0.71±0.10)IU/m L、凝血酶原时间为(14.14±2.75)S,活化的部分凝血活酶时间(APTT)为(34.88±4.86)S。残留白细胞计数(7.4±1.4)×104/L,经过数据统计学分析发现,采用亚甲蓝光法病毒灭活血浆后纤维蛋白原、凝血VIII因子、凝血酶原时间等指标无显著的变化。残留白细胞计数明显降低。结论:采用亚甲蓝光化学法灭活血浆病毒对凝血因子活性影响在合理范围之内,病毒灭活后血浆临床使用比较安全、有效。
Objective: To investigate the preparation of inactivated methylene blue virus plasma and its influence on blood coagulation factors. For clinical use of virus inactivated plasma therapy to provide dose and safe use basis. Provide a theoretical basis for the virus inactivated plasma. Methods: 100 plasma samples prepared from whole blood samples were collected for virus inactivation before and after the inactivation. Fresh frozen plasma was prepared and thawed. The changes of the active components and coagulation factors before and after inactivation were detected by methylene blue photochemical method. Results: Before inactivation, fibrinogen was (2.24 ± 0.12) mg / m L, blood coagulation factor VIII was (0.78 ± 0.09) IU / m L and prothrombin time was (14.02 ± 2.63) The APTT of enzyme was (34.62 ± 4.76) S. Residual leukocyte counts (3.0 ± 2.1) × 10 ~ 6 / L after inactivation of fibrinogen (2.10 ± 0.14) mg / m L, coagulation factor VIII was (0.71 ± 0.10) IU / m L, prothrombin time (14.14 ± 2.75) s, and the activated partial thromboplastin time (APTT) was (34.88 ± 4.86) s. Residual white blood cell count (7.4 ± 1.4) × 104 / L, after statistical analysis found that the use of methylene blue virus inactivation of plasma fibrinogen, coagulation factor VIII, prothrombin time and other indicators no significant change. Residual white blood cell count was significantly lower. Conclusion: The inactivation of plasma virus by methylene blue photochemical method has a reasonable influence on the activity of blood coagulation factors. The clinical use of plasma after inactivation of virus is safe and effective.